Related Experiment Videos
Depression in sarcoidosis.
B Chang1, J Steimel, D R Moller
1Department of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
American Journal of Respiratory and Critical Care Medicine
|February 17, 2001
Summary
Depression affects 60% of U.S. sarcoidosis patients, impacting their quality of life. Female sex, limited medical access, and breathing difficulties are key risk factors for depression in sarcoidosis.
Area of Science:
- Pulmonary Medicine
- Psychiatry
- Epidemiology
Background:
- Sarcoidosis is a chronic, multisystem inflammatory disease with significant impact on patient quality of life.
- Depression is a common comorbidity in chronic illnesses, yet its prevalence in U.S. sarcoidosis patients remained unquantified.
- This study aimed to determine depression prevalence and associated factors in a U.S. sarcoidosis cohort.
Discussion:
- The high prevalence of depression (60%) underscores the need for integrated mental health screening and support within sarcoidosis care.
- Factors such as female sex, reduced access to medical care, and increased dyspnea severity were significant predictors of depression.
- Despite access to tertiary care, patients reported limitations in medical care, highlighting systemic barriers.
Key Insights:
- Depression prevalence among U.S. sarcoidosis patients is 60%.
- Female gender, limited access to healthcare, and dyspnea are significant predictors of depression.
- Multisystem involvement in sarcoidosis correlates with increased depression risk.
Outlook:
- Future research should focus on developing and evaluating targeted interventions for depression in sarcoidosis.
- Healthcare providers need enhanced sensitivity to the barriers faced by sarcoidosis patients and should prioritize improving access to care.
- Integrating depression screening and management into routine sarcoidosis care is crucial for improving patient outcomes.